Plasma MiR-21: A potential diagnostic marker of colorectal cancer

Annals of Surgery

Volumn 256, Issue 3, 2012, Pages 544-551

  Kanaan, Ziad ^a   Rai, Shesh N ^a   Eichenberger, M Robert ^a   Roberts, Henry ^a   Keskey, Bobby ^a   Pan, Jianmin ^a   Galandiuk, Susan ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

biomarker; colorectal cancer; microRNA; MiR 21; plasma

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 133A; MICRORNA 135B; MICRORNA 21; MICRORNA 31; UNCLASSIFIED DRUG;

ADULT; AGED; BLOOD CHEMISTRY; CANCER PATIENT; CANCER TISSUE; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROFLUIDIC ANALYSIS; MICROFLUIDICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENETIC MARKERS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84865503318     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318265bd6f     Document Type: Conference Paper

References (54)

1. Janakiram NB, Rao CV. Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin. 2008;29:1-20.
2. Parkin DM. The global burden of urinary bladder cancer. Scand JUrol Nephrol. 2008;42:12-20.
3. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Atlanta: American Cancer Society, 2011.
4. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9:730-756.
5. O'Connell JB,Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-1425. (Pubitemid 39429665)
6. Zlobec I, Lugli A. Prognostic and predictive factors in colorectal cancer. J Clin Pathol. 2008;61:561-569. (Pubitemid 351688621)
7. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA. 2003;289:1288-1296. (Pubitemid 37432910)
8. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47:624-630. (Pubitemid 32275803)
9. Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology (Williston Park). 2006;20:579-587;discussion 588, 594, 596 passim. (Pubitemid 46940169)
10. Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467-477.
11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15-20. (Pubitemid 40094598)
12. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Bio. 2007;302:1-12. (Pubitemid 46096921)
13. Corte H, Manceau G, Blons H, et al. MicroRNA and colorectal cancer. Dig Liver Dis. 2012;44:195-200.
14. Chang KH, Miller N, Kheirelseid EAH, et al. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis. 2011;26:1415-1422.
15. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumourassociated microRNAs in serumof patientswith diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672-675. (Pubitemid 351667616)
16. Huang Z, Huang D, Ni S, et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127:118-126.
17. Pu X-x,Huang G-l,Guo H-q, et al. CirculatingmiR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674-1680.
18. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375-1381.
19. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila). 2010;3:1435-1442.
20. Link A, Balaguer F, Shen Y, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev. 2010;19:1766-1774.
21. Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer. World J Surg. 2009;33:638-646.
22. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011;80:193-208.
23. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-1474.
24. Kanaan Z, Rai SN, Eichenberger MR, et al. Differential microRNA expression tracks neoplastic progression in inflammatory bowel disease-associated colorectal cancer. Hum Mutat. 2012;33:551-560.
25. Galiveti CR, Rozhdestvensky TS, Brosius J, et al. Application of housekeeping npcRNAs for quantitative expression analysis of human transcriptome by realtime PCR. RNA. 2010;16:450-461.
26. Jung SH. Sample size for FDR-control in microarray data analysis. Bioinformatics. 2005;21:3097-3104.
27. The SAS System [computer program]. Version 9. Cary, NC: SAS Institute Inc; 2003.
28. Team RDC. R:ALanguage and Environment for Statistical Computing.Vienna, Austria: R Foundation for Statistical Computing; 2005.
29. GonenM. Receiver operating characteristics (ROC) curves. In: Proceedings of the 31st Annual SAS Users Group International Conference; 2006. Cary, NC: SAS Institute Inc Paper 210-231; 120.
30. Rai SN, Ray HE, Yuan X, et al. Statistical analysis of repeated microRNA high-throughput data with application to human heart failure: a review of methodology. Open Access Medical Statistics. 2012;2:21-31.
31. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285-1293.
32. Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57:84-91.
33. Liu R, ChenX,DuY, et al. Serum microRNAexpression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58:610-618.
34. Collins JF, Lieberman DA, Durbin TE, et al. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81-85.
35. Bartel DP.MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
36. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60.
37. Calin GA, CroceCM. MicroRNAsignatures in human cancers. NatRev Cancer. 2006;6:857-866.
38. Balaguer F, Link A, Lozano JJ, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 2010;70:6609-6618.
39. Toyota M, Suzuki H, Sasaki Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68:4123-4132.
40. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.
41. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223-7233.
42. Zen K, Zhang CY. Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2010;32:326-348.
43. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108-1113. (Pubitemid 350134889)
44. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 2010;285:35293-35302.
45. Chang KH, Miller N, Kheirelseid EA, et al. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg Oncol. 2011;37:597-603.
46. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2008;27:2128-2136. (Pubitemid 351485639)
47. Nagel R, le Sage C, Diosdado B, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68:5795-5802.
48. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene. 2007; 26:2799-2803. (Pubitemid 46663837)
49. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 2006;24:4677-4684. (Pubitemid 46630931)
50. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65:6029-6033. (Pubitemid 40994386)
51. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113-2129. (Pubitemid 43816961)
52. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269.
53. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 251:499-505.
54. Xiao J, Luo X, Lin H, et al. Retraction: microRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem. 2011;286:28656.